Latest Annual Report
Filed: 2026-03-31
Key Insights
- The company has two main operating segments - Drug Discovery Services and Compute Services and Treasury Management. Tracking the performance of these segments will be important for understanding the company's growth and profitability.
- The company has seen growth in its Series B Convertible Preferred Stock, Restricted Stock Units, Warrants, and Employee Stock Options, indicating potential dilution for existing shareholders that should be monitored.
- The company has a comprehensive cybersecurity risk management program overseen by the Board of Directors, which is a positive for mitigating operational risks.